In March 2026, ISO published the fourth edition of ISO 14155, replacing the third edition (ISO 14155:2020, now formally withdrawn). ISO 14155 is the internationally recognized Good Clinical Practice (GCP) standard for designing, conducting, recording, and reporting clinical investigations of medical devices in human subjects, and it underpins clinical investigation expectations referenced by regulators, notified bodies, and ethics committees worldwide, including under the EU MDR.
The standard’s core purpose is unchanged: protecting the rights, safety, and well-being of study subjects; ensuring scientifically sound and credible investigation results; and defining sponsor and principal investigator responsibilities. The most important changes relate to risk management, informed consent, eligibility criteria, Clinical Events Committees (CECs), Data Monitoring Committees (DMCs), and more detailed Clinical Investigation Plan (CIP) expectations for objectives, endpoints, and data analysis.
What actually changed in ISO 14155:2026:
- Refined definition of “clinical performance,” clarifying that not every investigation must provide direct benefit to participants (e.g., healthy-volunteer or data-collection studies)
- Restructured risk management: explicit separation between risks tied to device use and risks tied to CIP-mandated non-routine procedures, a new required residual risk assessment, and a consistency requirement across the CIP, investigator’s brochure, and informed consent materials
- Expanded ongoing risk management during study conduct, including clearer expectations for suspending enrollment or amending the protocol as new safety information emerges
- New section introducing Clinical Events Committees (CECs) — sponsors must consider establishing one, particularly for multicenter studies, with expectations for independence, responsibilities, and a formal charter
- Strengthened Data Monitoring Committee (DMC) expectations — charters must define the conditions for suspending, stopping, or modifying a study, and sponsors must justify in the CIP any decision not to use a DMC
- Informed consent updates: explicit recognition of consent via a legally designated representative, a new requirement that participants be given the opportunity to discuss participation with others (e.g., family), and more transparency on continued care and data use after withdrawal
- Deviations from eligibility criteria are now explicitly disallowed; any change requires a formal, reviewed CIP amendment
- Many requirements formerly confined to annexes (CIP content, study objectives, endpoints, data analysis) are now embedded directly in the normative core text
- New implant card requirement and clarified local-representative expectations for better alignment with national regulatory frameworks
- Incorporation of estimand principles into study design and statistical annexes, plus clarified guidance on non-inferiority margins and missing data
- New annex content on precautions, training on investigational device use, and in-silico testing; updated adverse event categorization to explicitly capture events associated with device deficiencies
Key takeaways:
- This is a refinement, not a reinvention, of the GCP framework the foundations of ISO 14155 are intact.
- But the added structure around risk categorization, CEC/DMC governance, and informed consent will touch nearly every active CIP and SOP written against ISO 14155:2020.
- Because ISO 14155 is widely incorporated by reference into regional frameworks (e.g., EU MDR), organizations shouldn’t wait for a formal transition mandate to start their gap assessment.
- ISO 14155:2026 is primarily a clarification and strengthening of existing GCP expectations rather than a complete redesign of the standard.
Regulators, notified bodies, and ethics committees are expected to reference ISO 14155:2026 as the updated GCP benchmark going forward, so it will shape both new study start-ups and, over time, how investigations already underway are reviewed. The revision raises the bar in areas with real patient-safety and data-credibility stakes clearer separation of device-use versus procedure-related risk, stronger CEC/DMC oversight expectations, and firmer boundaries around eligibility criteria while reinforcing informed consent as an ongoing, participant-centered process rather than a one-time signature. Because ISO 14155 is frequently incorporated by reference into national and regional regulatory frameworks (including EU MDR conformity assessment), gaps between current practice and the 2026 text can translate directly into audit findings, compliance observations, or delays in regulatory review.
Potential Impacts:
The 2026 revision of ISO 14155 may require organizations conducting or supporting medical device clinical investigations to update existing clinical procedures, templates, and study documentation to reflect the strengthened expectations for risk management, subject protection, safety oversight, and clinical investigation planning. Sponsors and study teams may need to reassess how investigation-related risks are identified and managed, how adverse events and device deficiencies are evaluated, and when independent oversight mechanisms such as Clinical Events Committees (CECs) or Data Monitoring Committees (DMCs) are appropriate. Updates may also be needed to informed consent processes, eligibility criteria management, Clinical Investigation Plans, statistical planning, and documentation practices. Overall, the revised standard is expected to increase the emphasis on proactive, risk-based clinical investigation management and may require additional training and procedural alignment for sponsors, investigators, CROs, and other clinical study personnel.
Organizations should review the 2026 revision of ISO 14155 against their current clinical investigation procedures and identify where updates are needed to maintain alignment with the revised standard. Priority should be given to reviewing risk-management processes, safety reporting and oversight, informed consent procedures, eligibility criteria management, Clinical Investigation Plan content, and the use of independent committees such as CECs and DMCs where appropriate. Related SOPs, work instructions, templates, and study documents should be updated as necessary, and affected clinical personnel should be trained on the revised expectations. For ongoing or planned clinical investigations, sponsors should also assess whether existing study documentation and oversight practices remain adequate or require revision under ISO 14155:2026.
AlvaMed can support organizations preparing for ISO 14155:2026 through gap assessments benchmarking current CIPs, SOPs, and risk management files against the new edition; updating CIP, informed consent, and CEC/DMC charter templates; and training clinical and regulatory teams on the revised requirements helping ensure new and ongoing investigations stay audit-ready as regulators and notified bodies transition to the new edition.
